Actively Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Led by Fudan University · Updated on 2026-03-25
1000
Participants Needed
2
Research Sites
174 weeks
Total Duration
On this page
Sponsors
F
Fudan University
Lead Sponsor
W
West China Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
CONDITIONS
Official Title
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and above, regardless of gender
- Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor
- Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy
- No obvious surgical contraindications
- Able to comply with research plans, follow-up plans, and other protocol requirements
- Voluntary participation and signed informed consent
You will not qualify if you...
- Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor
- Currently diagnosed with other types of tumors or any cancer history
- Diagnosed with familial syndromes
- Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy
- Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw
- Recipient of blood transfusion within 30 days prior to study blood draw
- Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
- Poor health condition and not suitable for blood draw
- Any other disease/condition deemed not suitable for study enrollment by researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Fudan University shanghai cancer center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
2
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
X
Xianjun Yu, MD, PhD
CONTACT
S
Shunrong Ji, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here